Uncategorized

Regulators tune the Volcker rule

| January 31, 2020

This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors.

Small changes can make a big difference when it comes to the way banks manage their current $13.8 trillion in assets. And regulators in the last few days have recommended some small changes in the Volcker rule governing bank investment in debt and credit funds. The market in CLOs and leveraged credit seems the clearest potential beneficiary, although other corners of the capital markets could see new bank interest, too.

Constraints on CLOs

Even though banks currently hold around $90 billion in CLOs mainly in ‘AAA’ classes, regulations have sometimes clouded banks’ ability to invest. The Volcker rule intended to eliminate bank investment in funds that could put insured deposits at risk but excluded loan securitizations from that list of funds. The rule has led CLOs to hold only leveraged loans and exclude high yield debt. It has also ruled out CLO participation in debt restructurings that might exchange loans for equity or related instruments—limiting CLOs ability to manage distressed credits.

Volcker also stops banks from holding ownership interests in funds, which some regulators interpret broadly to include debt interests with the right fire a manager for cause. Most ‘AAA’ CLOs have this right, although banks have differed in their willingness risk an interpretation that ‘AAA’ CLOs violate Volcker.

Litigation has also challenged bank holdings of CLOs. A suit pending against JP Morgan, Kirschner v. JP Morgan et al., argues that the term loans usually held by CLOs fall under federal securities laws and do not qualify for the Volcker allowance for loan securitizations. If that suit were decided against JP Morgan, banks potentially would need to sell their current CLO holdings.

Addressed by the latest proposed changes

Some of the key provisions of the Fed’s latest proposal address constraints around CLOs as well as potentially expanding bank investment in other types of debt funds, business development companies and the like (Exhibit 1). The proposed changes would allow banks to invest in funds with up to 5% of assets in non-loan instruments, opening the door to holdings of high yield debt, equity, warrants and other instruments. The proposal also specifies that funds could hold a limited amount of equity associated with loans or debt, which seems targeted to allowing funds to participate in debt restructurings. The proposal specifies that the ability of a debt holder to fire a manager for cause would not constitute an ownership interest. And the proposal creates a safe harbor from litigation like Kirschner v. JP Morgan, laying out criteria that most CLO loans and high yield debt would be able to meet.

Other areas, too

Banks could become more invested in business development companies under the proposed changes, getting more exposure to the middle market loans usually owned by those investors. And banks could invest in securitizations that included mortgage servicing and leases.

Most of these changes seem reasonable clarifications of grey areas in the Volcker rule. Banks sidelined by earlier uncertainty around the rule seem likely to take a new look at a range of assets, especially CLOs and especially in a market where yield is increasingly hard to find.

Exhibit 1: A summary of key Fed proposed modifications to the Volcker rule

Source: Federal Reserve Board, Amherst Pierpont Securities

***

The view in rates

The sharp drop in rates over the last two weeks seems equal parts fact and fear, and fear seems to be winning. The fact part highlights the growth in China’s share of global GDP since the SARS outbreak in 2003: around 4% then, around 19% now. So it is true that the current quarantines in China, the restrictions on travel and the like have almost certainly hurt China’s GDP. Of course, it is likely that pent up demand would resurface once there’s clarity on the coronavirus and GDP would partially or fully catch up. The fear part revolves around scenarios that hint of pandemic. At this point, the coronavirus seems roughly as contagious as SARS but much less fatal, and estimated time to a tested and approved vaccine ranges from a year or more.  Given the emerging scientific and public health collaboration to address the outbreak, it seems likely that the uncertainty around the outbreak will fall quickly. As it falls, rates should rise.

The view in spreads

The appetite for spread and compounding income is still strong, but investors have clearly stepped back to watch the coronavirus play out. It seems reasonable. After all, it’s a risk that’s undoubtedly hard to price. Still, the US economy looks healthy enough to keep credit concerns at bay for investment grade companies and even most high yield companies, so spreads have room to compress further once uncertainty around the virus drops. MBS has some room to run tighter even though low rates stand to keep prepayments elevated through the spring, especially in Ginnie Mae MBS. If the economy moves above current expectations of less than 2% real GDP growth, spreads should tighten further.

The view in credit

A variety of measures of corporate leverage remain high, but leverage spells trouble only if growth falls below current expectations and financing for leveraged borrowers tightens. That does not look likely. It looks more likely growth might slightly exceed expectations, lifting corporate fundaments. As for the consumer, that is a story of generally continued strength with low unemployment, strong income, rising net worth and low debt service as a share of income.

admin
jkillian@apsec.com
john.killian@santander.us 1 (646) 776-7714

This material is intended only for institutional investors and does not carry all of the independence and disclosure standards of retail debt research reports. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.

This message, including any attachments or links contained herein, is subject to important disclaimers, conditions, and disclosures regarding Electronic Communications, which you can find at https://portfolio-strategy.apsec.com/sancap-disclaimers-and-disclosures.

Important Disclaimers

Copyright © 2024 Santander US Capital Markets LLC and its affiliates (“SCM”). All rights reserved. SCM is a member of FINRA and SIPC. This material is intended for limited distribution to institutions only and is not publicly available. Any unauthorized use or disclosure is prohibited.

In making this material available, SCM (i) is not providing any advice to the recipient, including, without limitation, any advice as to investment, legal, accounting, tax and financial matters, (ii) is not acting as an advisor or fiduciary in respect of the recipient, (iii) is not making any predictions or projections and (iv) intends that any recipient to which SCM has provided this material is an “institutional investor” (as defined under applicable law and regulation, including FINRA Rule 4512 and that this material will not be disseminated, in whole or part, to any third party by the recipient.

The author of this material is an economist, desk strategist or trader. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM or any of its affiliates may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.

This material (i) has been prepared for information purposes only and does not constitute a solicitation or an offer to buy or sell any securities, related investments or other financial instruments, (ii) is neither research, a “research report” as commonly understood under the securities laws and regulations promulgated thereunder nor the product of a research department, (iii) or parts thereof may have been obtained from various sources, the reliability of which has not been verified and cannot be guaranteed by SCM, (iv) should not be reproduced or disclosed to any other person, without SCM’s prior consent and (v) is not intended for distribution in any jurisdiction in which its distribution would be prohibited.

In connection with this material, SCM (i) makes no representation or warranties as to the appropriateness or reliance for use in any transaction or as to the permissibility or legality of any financial instrument in any jurisdiction, (ii) believes the information in this material to be reliable, has not independently verified such information and makes no representation, express or implied, with regard to the accuracy or completeness of such information, (iii) accepts no responsibility or liability as to any reliance placed, or investment decision made, on the basis of such information by the recipient and (iv) does not undertake, and disclaims any duty to undertake, to update or to revise the information contained in this material.

Unless otherwise stated, the views, opinions, forecasts, valuations, or estimates contained in this material are those solely of the author, as of the date of publication of this material, and are subject to change without notice. The recipient of this material should make an independent evaluation of this information and make such other investigations as the recipient considers necessary (including obtaining independent financial advice), before transacting in any financial market or instrument discussed in or related to this material.

The Library

Search Articles